2024年4月10日，中国国家药品监督管理局药品审评中心（CDE）在其官方网站上宣布，天士力公司研发的一类新药P134细胞注射液已获得临床试验批准，该药物计划用于复发性胶质母细胞瘤的治疗。据天士力公司公告，这款创新生物药物是天士力与北京神经外科研究所合作开发的，是一种针对CD44和/或CD133的自体CAR-T细胞产品。这是该产品在中国首次获得临床试验批准（IND）。胶质瘤是源自中枢神经系统（...
Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments